Xiamen Junde Pharmaceutical Technology Co., Ltd., a China-based pharmaceutical company, has entered into a licensing agreement with Changchun GeneScience Pharmaceutical Co., Ltd., granting the latter exclusive commercialization rights for JTX-102, a gastric volume-occupying and weight-reducing capsule, across China, including mainland China, Hong Kong, and Macau. Under the terms of the agreement, Junde is set to receive an upfront payment of up to RMB 100 million (approximately USD 14 million), along with future milestone payments and royalties on subsequent sales.
JTX-102 is notable for being the first of its kind to complete clinical development and file for marketing approval in China for the treatment of obesity and weight management. This agreement positions Changchun GeneScience to leverage JTX-102’s innovative approach in addressing the growing obesity epidemic in the region, while also enhancing Junde’s financial outlook through potential future earnings from the product.- Flcube.com
